I 

118TH CONGRESS 

2D SESSION H. R. 8601 

To amend the Public Health Service Act to provide for and support liver 

illness visibility, education, and research, and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

JUNE 3, 2024 

Ms. VELA ́ZQUEZ (for herself, Mr. BOWMAN, Ms. MENG, Ms. SCHAKOWSKY, 

Ms. BARRAGA ́N, Ms. JACKSON LEE, Mr. GRIJALVA, and Mr. JOHNSON

of Georgia) introduced the following bill; which was referred to the Committee on Energy and Commerce 

A BILL 

To amend the Public Health Service Act to provide for 

and support liver illness visibility, education, and research, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Liver Illness Visibility, 

5 Education, and Research Act of 2024’’. 

6 SEC. 2. FINDINGS. 

7 Congress finds the following: 

8 (1) Liver cancer is among the leading causes of 

9 cancer deaths globally. 


ssavage on LAPJG3WLY3PROD with BILLS
2 

•HR 8601 IH

1 (2) In 2023, approximately 41,630 people in 

2 the United States were diagnosed with primary liver 

3 cancer, and approximately 29,840 died from the dis4 ease. 

5 (3) Liver cancer is a leading cause of cancer 

6 death among the Asian-American, Pacific Islander, 

7 and Hispanic communities. 

8 (4) The most vulnerable Asian-Americans are 

9 those who are foreign-born, low-income, and living in 

10 ethnic enclaves. 

11 (5) Asian and Pacific Islander men and women 

12 are more than twice as likely to develop liver cancer 

13 compared to the non-Hispanic White population. 

14 (6) Among the Asian and Pacific Islander pop15 ulation, the higher incidence rate of liver cancer is 

16 partially explained by higher incidence rates of Hep17 atitis B and diabetes, which are comorbidities shown 

18 to increase an individual’s risk of developing liver 

19 cancer. 

20 (7) The most common causes of liver cancer in21 clude Hepatitis B virus and Hepatitis C virus infec22 tion. 

23 (8) Hepatitis B is a primary risk factor for de24 veloping liver cancer, and 1 in 4 of those chronically 


ssavage on LAPJG3WLY3PROD with BILLS
3 

•HR 8601 IH

1 infected with hepatitis B develop cirrhosis, liver fail2 ure, or liver cancer. 

3 (9) Half of all individuals with hepatitis B in 

4 the United States are Asian-American or Pacific Is5 lander, though this group accounts for only 5 per6 cent of the U.S. population. 

7 (10) Among African immigrants in the United 

8 States, the prevalence of hepatitis B infection is ap9 proximately 1 in 10, and African immigrants make 

10 up 30 percent of those with chronic hepatitis B in11 fection in the United States. 

12 (11) Among Hispanic/Latino communities, liver 

13 cancer incidence and death rates are twice as high 

14 compared to the non-Hispanic White population. 

15 (12) Hispanics/Latinos are 60 percent more 

16 likely to die from viral hepatitis than non-Hispanic 

17 Whites. 

18 SEC. 3. LIVER CANCER AND DISEASE RESEARCH. 

19 Subpart 1 of part C of title IV of the Public Health 

20 Service Act (42 U.S.C. 285 et seq.) is amended by adding 

21 at the end the following new section: 

22 ‘‘SEC. 417H. LIVER CANCER AND DISEASE RESEARCH. 

23 ‘‘(a) EXPANSION AND COORDINATION OF ACTIVI24 TIES.—The Director of the Institute shall expand, intenVerDate Sep 11 2014 18:50 Jul 19, 2024 Jkt 049200 PO 00000 Frm 00003 Fmt 6652 Sfmt 6201 E:\BILLS\H8601.IH H8601

ssavage on LAPJG3WLY3PROD with BILLS
4 

•HR 8601 IH

1 sify, and coordinate the activities of the Institute with re2 spect to research on liver cancer and other liver diseases. 

3 ‘‘(b) PROGRAMS FOR LIVER CANCER.—In carrying 

4 out subsection (a), the Director of the Institute shall— 

5 ‘‘(1) provide for an expansion and intensifica6 tion of the conduct and support of— 

7 ‘‘(A) basic research concerning the etiology 

8 and causes of liver cancer; 

9 ‘‘(B) clinical research and related activities 

10 concerning the causes, prevention, detection, 

11 and treatment of liver cancer; 

12 ‘‘(C) control programs with respect to liver 

13 cancer, in accordance with section 412, includ14 ing community-based programs designed to as15 sist members of medically underserved popu16 lations (including women), low-income popu17 lations, or minority groups; and 

18 ‘‘(D) information and education programs 

19 with respect to liver cancer, in accordance with 

20 section 413; 

21 ‘‘(2) issue targeted calls for proposals from re22 search scientists for purposes of funding priority 

23 areas of liver cancer research; 

24 ‘‘(3) establish a special emphasis panel (as de25 fined by the National Institutes of Health) to review 


ssavage on LAPJG3WLY3PROD with BILLS
5 

•HR 8601 IH

1 any proposal submitted pursuant to paragraph (2); 

2 and 

3 ‘‘(4) based on reviews by the special emphasis 

4 panel under paragraph (3), select which proposals to 

5 fund or support. 

6 ‘‘(c) INTER-INSTITUTE WORKING GROUP.—The Di7 rector of the Institute shall establish an inter-institute 

8 working group to coordinate research agendas focused on 

9 finding better outcomes and cures for liver cancer and 

10 other liver diseases, including hepatitis B. 

11 ‘‘(d) GRANTS AND COOPERATIVE AGREEMENTS.— 

12 ‘‘(1) IN GENERAL.—The Secretary may award 

13 grants and enter into cooperative agreements with 

14 entities for the purpose of expanding and supporting 

15 research on— 

16 ‘‘(A) conditions known to increase an indi17 vidual’s risk of developing a major liver disease, 

18 such as liver cancer, hepatitis B, hepatitis C, 

19 nonalcoholic fatty liver disease, and cirrhosis of 

20 the liver; and 

21 ‘‘(B) opportunities for preventative and di22 agnostic measures for such a disease, including 

23 the study of molecular pathology and biomark24 ers for early detection of such disease. 


ssavage on LAPJG3WLY3PROD with BILLS
6 

•HR 8601 IH

1 ‘‘(2) EXPERIMENTAL TREATMENT AND PRE2 VENTION.—In the case of an entity that is a hospital 

3 or a health care facility, the Secretary may award a 

4 grant or enter into a cooperative agreement with 

5 such an entity for the purpose of supporting an ex6 perimental treatment or prevention program for liver 

7 cancer carried out by such entity. 

8 ‘‘(3) AUTHORIZATION OF APPROPRIATIONS.— 

9 For purposes of carrying out this subsection, there 

10 is authorized to be appropriated $45,000,000 for 

11 each of fiscal years 2025 through 2029. Any 

12 amounts appropriated under this paragraph shall re13 main available until expended.’’. 

14 SEC. 4. LIVER CANCER AND DISEASE PREVENTION, AWARE15 NESS, AND PATIENT TRACKING GRANTS. 

16 Subpart I of part D of title III of the Public Health 

17 Service Act (42 U.S.C. 254b et seq.) is amended by adding 

18 at the end the following new section: 

19 ‘‘SEC. 330Q. LIVER CANCER AND DISEASE PREVENTION, 

20 AWARENESS, AND PATIENT TRACKING 

21 GRANTS. 

22 ‘‘(a) PREVENTION INITIATIVE GRANT PROGRAM.— 

23 ‘‘(1) IN GENERAL.—The Secretary, through the 

24 Director of the Centers for Disease Control and Pre25 vention, may award grants and enter into cooperaVerDate Sep 11 2014 18:50 Jul 19, 2024 Jkt 049200 PO 00000 Frm 00006 Fmt 6652 Sfmt 6201 E:\BILLS\H8601.IH H8601

ssavage on LAPJG3WLY3PROD with BILLS
7 

•HR 8601 IH

1 tive agreements with entities for the purpose of ex2 panding and supporting— 

3 ‘‘(A) prevention activities (including pro4 viding screenings, vaccinations, or other pre5 ventative treatment) for conditions known to in6 crease an individual’s risk of developing a major 

7 liver disease, such as liver cancer, hepatitis B, 

8 hepatitis C, nonalcoholic fatty liver disease, and 

9 cirrhosis of the liver; 

10 ‘‘(B) activities relating to surveillance, 

11 diagnostics, and provision of guidance for indi12 viduals at high risk for contracting liver cancer 

13 and other liver diseases; and 

14 ‘‘(C) a robust hepatitis surveillance infra15 structure to provide for timely and accurate in16 formation regarding progress to eliminate viral 

17 hepatitis. 

18 ‘‘(2) REPORT.—An entity that receives a grant 

19 or cooperative agreement under paragraph (1) shall 

20 submit to the Secretary, at a time specified by the 

21 Secretary, a report describing each activity carried 

22 out pursuant to such paragraph and evaluating the 

23 effectiveness of such activity in promoting prevention 

24 and treatment of liver cancer and other liver dis25 eases. 


ssavage on LAPJG3WLY3PROD with BILLS
8 

•HR 8601 IH

1 ‘‘(3) AUTHORIZATION OF APPROPRIATIONS.— 

2 For purposes of carrying out this subsection, there 

3 is authorized to be appropriated $90,000,000 for 

4 each of fiscal years 2025 through 2029. Any 

5 amounts appropriated under this paragraph shall re6 main available until expended and shall be used to 

7 supplement and not supplant other Federal funds 

8 provided for activities under this subsection. 

9 ‘‘(b) AWARENESS INITIATIVE GRANT PROGRAM.— 

10 ‘‘(1) IN GENERAL.—The Secretary, through the 

11 Director of the Centers for Disease Control and Pre12 vention, may award grants to eligible entities for the 

13 purpose of raising awareness for liver cancer and 

14 other liver diseases, which may include the produc15 tion, dissemination, and distribution of informational 

16 materials targeted towards communities and popu17 lations with a higher risk for developing liver cancer 

18 and other liver diseases. 

19 ‘‘(2) ELIGIBLE ENTITIES.—To be eligible to re20 ceive a grant under paragraph (1), an entity shall 

21 submit to the Secretary an application, at such time, 

22 in such manner, and containing such information as 

23 the Secretary may require, including a description of 

24 how the entity, in disseminating information on liver 


ssavage on LAPJG3WLY3PROD with BILLS
9 

•HR 8601 IH

1 cancer and other liver diseases pursuant to para2 graph (1), will— 

3 ‘‘(A) with respect to any community or 

4 population, consult with members of such com5 munity or population and provide such informa6 tion in a manner that is culturally and linguis7 tically appropriate for such community or popu8 lation; 

9 ‘‘(B) highlight the range of treatments 

10 available for liver cancer and other liver dis11 eases; 

12 ‘‘(C) integrate information on available 

13 hepatitis B and hepatitis C testing programs 

14 into any liver cancer presentations carried out 

15 by the entity; and 

16 ‘‘(D) target communities and populations 

17 with a higher risk for contracting liver cancer 

18 and other liver diseases. 

19 ‘‘(3) PREFERENCE.—In awarding grants under 

20 paragraph (1), the Secretary shall give preference to 

21 entities that— 

22 ‘‘(A) are, or work with, a Federally quali23 fied health center; or 

24 ‘‘(B) are community-based organizations. 


ssavage on LAPJG3WLY3PROD with BILLS
10 

•HR 8601 IH

1 ‘‘(4) REPORT.—An entity that receives a grant 

2 under paragraph (1) shall submit to the Secretary, 

3 at a time specified by the Secretary, a report de4 scribing each activity carried out pursuant to such 

5 paragraph and evaluating the effectiveness of such 

6 activity in raising awareness for liver cancer and 

7 other liver diseases. 

8 ‘‘(5) AUTHORIZATION OF APPROPRIATIONS.— 

9 For purposes of carrying out this subsection, there 

10 is authorized to be appropriated $10,000,000 for 

11 each of fiscal years 2025 through 2029. Any 

12 amounts appropriated under this paragraph shall re13 main available until expended and shall be used to 

14 supplement and not supplant other Federal funds 

15 provided for activities under this subsection.’’. 

16 SEC. 5. HEPATITIS B RESEARCH. 

17 Subpart 3 of part C of title IV of the Public Health 

18 Service Act (42 U.S.C. 285c et seq.) is amended by adding 

19 at the end the following new section: 

20 ‘‘SEC. 434B. HEPATITIS B. 

21 ‘‘The Director of the Institute shall, in collaboration 

22 with the Director of the National Institute of Allergy and 

23 Infectious Diseases, issue targeted calls for hepatitis B re24 search proposals focused on key research questions identiVerDate Sep 11 2014 18:50 Jul 19, 2024 Jkt 049200 PO 00000 Frm 00010 Fmt 6652 Sfmt 6201 E:\BILLS\H8601.IH H8601

ssavage on LAPJG3WLY3PROD with BILLS
11 

•HR 8601 IH

1 fied by the research community and discussed in peer-re2 viewed research journal articles.’’. 

3 SEC. 6. CHANGES RELATING TO NATIONAL INSTITUTE OF 

4 DIABETES AND DIGESTIVE AND KIDNEY DIS5 EASES. 

6 (a) CHANGE OF NAME OF NATIONAL INSTITUTE OF

7 DIABETES AND DIGESTIVE AND KIDNEY DISEASES.— 

8 (1) IN GENERAL.—Subpart 3 of part C of title 

9 IV of the Public Health Service Act (42 U.S.C. 285c 

10 et seq.) is amended in the subpart heading by strik11 ing ‘‘National Institute of Diabetes and Di12 gestive and Kidney Diseases’’ and inserting 

13 ‘‘National Institute of Diabetes and Diges14 tive, Kidney, and Liver Diseases’’. 

15 (2) TREATMENT OF DIRECTOR OF NATIONAL

16 INSTITUTE OF DIABETES AND DIGESTIVE AND KID17 NEY DISEASES.—The individual serving as the Di18 rector of the National Institute of Diabetes and Di19 gestive and Kidney Diseases as of the date of enact20 ment of this Act may continue to serve as the Direc21 tor of the National Institute of Diabetes and Diges22 tive, Kidney, and Liver Diseases commencing as of 

23 that date. 

24 (3) REFERENCES.—Any reference to the Na25 tional Institute of Diabetes and Digestive and KidVerDate Sep 11 2014 18:50 Jul 19, 2024 Jkt 049200 PO 00000 Frm 00011 Fmt 6652 Sfmt 6201 E:\BILLS\H8601.IH H8601

ssavage on LAPJG3WLY3PROD with BILLS
12 

•HR 8601 IH

1 ney Diseases, or the Director of the National Insti2 tute of Diabetes and Digestive and Kidney Diseases, 

3 in any law, regulation, document, record, or other 

4 paper of the United States shall be deemed to be a 

5 reference to the National Institute of Diabetes and 

6 Digestive, Kidney, and Liver Diseases, or the Direc7 tor of the National Institute of Diabetes and Diges8 tive, Kidney, and Liver Diseases, respectively. 

9 (4) CONFORMING AMENDMENTS.— 

10 (A) Section 401(b)(3) of the Public Health 

11 Service Act (42 U.S.C. 281(b)(3)) is amended 

12 by striking ‘‘The National Institute of Diabetes 

13 and Digestive and Kidney Diseases.’’ and in14 serting ‘‘The National Institute of Diabetes and 

15 Digestive, Kidney, and Liver Diseases.’’. 

16 (B) Section 409A(a) of the Public Health 

17 Service Act (42 U.S.C. 284e(a)) is amended by 

18 striking ‘‘the National Institute of Diabetes and 

19 Digestive and Kidney Diseases’’ and inserting 

20 ‘‘the National Institute of Diabetes and Diges21 tive, Kidney, and Liver Diseases’’. 

22 (b) PURPOSE OF THE INSTITUTE.—Section 426 of 

23 the Public Health Service Act (42 U.S.C. 285c) is amend24 ed— 


ssavage on LAPJG3WLY3PROD with BILLS
13 

•HR 8601 IH

1 (1) by striking ‘‘National Institute of Diabetes 

2 and Digestive and Kidney Diseases’’ and inserting 

3 ‘‘National Institute of Diabetes and Digestive, Kid4 ney, and Liver Diseases’’; and 

5 (2) by striking ‘‘and kidney, urologic, and hem6 atologic diseases’’ and inserting ‘‘kidney, urologic, 

7 and hematologic diseases, and liver diseases’’. 

8 (c) DATA SYSTEMS AND INFORMATION CLEARING9 HOUSES.—Section 427 of the Public Health Service Act 

10 (42 U.S.C. 285c–1) is amended by adding at the end the 

11 following new subsection: 

12 ‘‘(d) The Director of the Institute shall (1) establish 

13 the National Liver Diseases Data System for the collec14 tion, storage, analysis, retrieval, and dissemination of data 

15 derived from patient populations with liver diseases, in16 cluding, where possible, data involving general populations 

17 for the purpose of detection of individuals with a risk of 

18 developing liver diseases, and (2) establish the National 

19 Liver Diseases Information Clearinghouse to facilitate and 

20 enhance knowledge and understanding of liver diseases on 

21 the part of health professionals, patients, and the public 

22 through the effective dissemination of information.’’. 

23 (d) REESTABLISHMENT OF LIVER DISEASE RE24 SEARCH BRANCH WITHIN DIVISION OF DIGESTIVE DISVerDate Sep 11 2014 18:50 Jul 19, 2024 Jkt 049200 PO 00000 Frm 00013 Fmt 6652 Sfmt 6201 E:\BILLS\H8601.IH H8601

ssavage on LAPJG3WLY3PROD with BILLS
14 

•HR 8601 IH

1 EASES AND NUTRITION AS DIVISION OF LIVER DIS2 EASES.— 

3 (1) IN GENERAL.—The Liver Disease Research 

4 Branch within the Division of Digestive Diseases 

5 and Nutrition of the National Institute of Diabetes 

6 and Digestive and Kidney Diseases (referred to in 

7 this subsection as the ‘‘Liver Disease Research 

8 Branch’’) is hereby redesignated and promoted as 

9 the Division of Liver Diseases, which shall be within 

10 the National Institute of Diabetes and Digestive, 

11 Kidney, and Liver Diseases, as redesignated by sub12 section (a), as a separate division from the other di13 visions within such Institute. 

14 (2) DIVISION DIRECTOR.—Section 428 of the 

15 Public Health Service Act (42 U.S.C. 285c–2) is 

16 amended— 

17 (A) in the section heading, by striking 

18 ‘‘DIVISION DIRECTORS FOR DIABETES, EN19 DOCRINOLOGY, AND METABOLIC DIS20 EASES, DIGESTIVE DISEASES AND NUTRI21 TION, AND KIDNEY, UROLOGIC, AND HEM22 ATOLOGIC DISEASES’’ and inserting ‘‘DIVI23 SION DIRECTORS FOR DIABETES, ENDO24 CRINOLOGY, AND METABOLIC DISEASES, 

25 DIGESTIVE DISEASES AND NUTRITION, 


ssavage on LAPJG3WLY3PROD with BILLS
15 

•HR 8601 IH

1 KIDNEY, UROLOGIC, AND HEMATOLOGIC

2 DISEASES, AND LIVER DISEASES’’; 

3 (B) in subsection (a)(1)— 

4 (i) in the matter preceding subpara5 graph (A), by striking ‘‘and a Division Di6 rector for Kidney, Urologic, and Hemato7 logic Diseases’’ and inserting ‘‘a Division 

8 Director for Kidney, Urologic, and Hem9 atologic Diseases, and a Division Director 

10 for Liver Diseases’’; and 

11 (ii) in subparagraph (A), by striking 

12 ‘‘and kidney, urologic, and hematologic dis13 eases’’ and inserting ‘‘kidney, urologic, and 

14 hematologic diseases, and liver diseases’’; 

15 and 

16 (C) in subsection (b)— 

17 (i) in the matter preceding paragraph 

18 (1), by striking ‘‘and the Division Director 

19 for Kidney, Urologic, and Hematologic 

20 Diseases’’ and inserting ‘‘the Division Di21 rector for Kidney, Urologic, and Hemato22 logic Diseases, and the Division Director 

23 for Liver Diseases’’; and 

24 (ii) in paragraph (1), by striking ‘‘and 

25 kidney, urologic, and hematologic diseases’’ 


ssavage on LAPJG3WLY3PROD with BILLS
16 

•HR 8601 IH

1 and inserting ‘‘kidney, urologic, and hem2 atologic diseases, and liver diseases’’. 

3 (3) TREATMENT OF DIRECTOR OF LIVER DIS4 EASE RESEARCH BRANCH.—The individual serving 

5 as the Director of the Liver Disease Research 

6 Branch as of the date of enactment of this Act may 

7 continue to serve as the Division Director for Liver 

8 Diseases commencing as of that date. 

9 (4) TRANSFER OF AUTHORITIES.—The Sec10 retary of Health and Human Services shall delegate 

11 to the Division Director for Liver Diseases all duties 

12 and authorities that were vested in the Director of 

13 the Liver Disease Research Branch as of the day be14 fore the date of enactment of this Act. 

15 (5) REFERENCES.—Any reference to the Liver 

16 Disease Research Branch, or the Director of the 

17 Liver Disease Research Branch, in any law, regula18 tion, document, record, or other paper of the United 

19 States shall be deemed to be a reference to the Divi20 sion of Liver Diseases, or the Division Director for 

21 Liver Diseases, respectively. 

22 (e) INTERAGENCY COORDINATING COMMITTEES.— 

23 Section 429(a) of the Public Health Service Act (42 

24 U.S.C. 285c–3(a)) is amended— 


ssavage on LAPJG3WLY3PROD with BILLS
17 

•HR 8601 IH

1 (1) in paragraph (1), by striking ‘‘and kidney, 

2 urologic, and hematologic diseases’’ and inserting 

3 ‘‘kidney, urologic, and hematologic diseases, and 

4 liver diseases’’; and 

5 (2) in the matter following paragraph (2), by 

6 striking ‘‘and a Kidney, Urologic, and Hematologic 

7 Diseases Coordinating Committee’’ and inserting ‘‘a 

8 Kidney, Urologic, and Hematologic Diseases Coordi9 nating Committee, and a Liver Diseases Coordi10 nating Committee’’. 

11 (f) ADVISORY BOARDS.—Section 430 of the Public 

12 Health Service Act (42 U.S.C. 285c–4) is amended— 

13 (1) in subsection (a), by striking ‘‘and the Na14 tional Kidney and Urologic Diseases Advisory 

15 Board’’ and inserting ‘‘the National Kidney and 

16 Urologic Diseases Advisory Board, and the Liver 

17 Diseases Advisory Board’’; and 

18 (2) in subsection (b)(2)(A)(i)— 

19 (A) by striking ‘‘the Director of the Na20 tional Institute of Diabetes and Digestive and 

21 Kidney Diseases’’ and inserting ‘‘the Director 

22 of the National Institute of Diabetes and Diges23 tive, Kidney, and Liver Diseases’’; and 

24 (B) by striking ‘‘and the Division Director 

25 of the National Institute of Diabetes and DigesVerDate Sep 11 2014 18:50 Jul 19, 2024 Jkt 049200 PO 00000 Frm 00017 Fmt 6652 Sfmt 6201 E:\BILLS\H8601.IH H8601

ssavage on LAPJG3WLY3PROD with BILLS
18 

•HR 8601 IH

1 tive and Kidney Diseases’’ and inserting ‘‘and 

2 the Division Director of the National Institute 

3 of Diabetes and Digestive, Kidney, and Liver 

4 Diseases’’. 

5 (g) RESEARCH AND TRAINING CENTERS.—Section 

6 431 of the Public Health Service Act (42 U.S.C. 285c– 

7 5) is amended— 

8 (1) by redesignating subsection (e) as sub9 section (f); and 

10 (2) by inserting after subsection (d) the fol11 lowing new subsection: 

12 ‘‘(e) The Director of the Institute shall provide for 

13 the development or substantial expansion of centers for 

14 research in liver diseases. Each center developed or ex15 panded under this subsection— 

16 ‘‘(1) shall utilize the facilities of a single insti17 tution, or be formed from a consortium of cooper18 ating institutions, meeting such research qualifica19 tions as may be prescribed by the Secretary; 

20 ‘‘(2) shall develop and conduct basic and clin21 ical research into the cause, diagnosis, early detec22 tion, prevention, control, and treatment of liver dis23 eases and related functional, congenital, metabolic, 

24 or other complications resulting from such diseases; 


ssavage on LAPJG3WLY3PROD with BILLS
19 

•HR 8601 IH

1 ‘‘(3) shall encourage research into and pro2 grams for— 

3 ‘‘(A) providing information for patients 

4 with such diseases and complications and the 

5 families of such patients, physicians and others 

6 who care for such patients, and the general 

7 public; 

8 ‘‘(B) model programs for cost effective and 

9 preventive patient care; and 

10 ‘‘(C) training physicians and scientists in 

11 research on such diseases and complications; 

12 and 

13 ‘‘(4) may perform research and participate in 

14 epidemiological studies and data collection relevant 

15 to liver diseases in order to disseminate such re16 search, studies, and data to the health care profes17 sion and to the public.’’. 

18 (h) ADVISORY COUNCIL SUBCOMMITTEES.—Section 

19 432 of the Public Health Service Act (42 U.S.C. 285c– 

20 6) is amended— 

21 (1) by striking ‘‘and a subcommittee on kidney, 

22 urologic, and hematologic diseases’’ and inserting ‘‘a 

23 subcommittee on kidney, urologic, and hematologic 

24 diseases, and a subcommittee on liver diseases’’; and 


ssavage on LAPJG3WLY3PROD with BILLS
20 

•HR 8601 IH

1 (2) by striking ‘‘and kidney, urologic, and hem2 atologic diseases’’ and inserting ‘‘kidney, urologic, 

3 and hematologic diseases, and liver diseases’’. 

Æ 


ssavage on LAPJG3WLY3PROD with BILLS